Walsh A, Ito Y, Breslow J L
Rockefeller University, New York, New York 10021.
J Biol Chem. 1989 Apr 15;264(11):6488-94.
Five lines of transgenic mice, which had integrated the human apolipoprotein (apo) A-I gene and various amounts of flanking sequences, were established. Normally, apoA-I is expressed mainly in liver and intestine, but all of the transgenic lines only expressed apoA-I mRNA in liver, strongly suggesting that 256 base pairs of 5'-flanking sequence was sufficient for liver apoA-I gene expression but that 5.5 kilobase pairs was not sufficient for intestinal expression. Mean plasma levels of human apoA-I varied in different lines from approximately 0.1 to 200% of normal mouse levels. This was not dependent on the amount of flanking sequence. Lipoprotein levels were studied in detail in one of the lines with a significantly increased apoA-I pool size. In one study, the total plasma apoA-I level (mouse plus human) was 381 +/- 43 mg/dl in six animals from this line, compared to 153 +/- 17 mg/dl in matched controls. Total and high density lipoprotein cholesterol (HDL-C) levels were increased 60% in transgenic animals, compared to controls (total cholesterol: 125 +/- 12 versus 78 +/- 13 mg/dl, p = 0.0001; HDL-C 90 +/- 7 versus 55 +/- 11 mg/dl, p = 0.0001). The molar ratio of HDL-C/apoA-I was significantly lower in transgenic animals, 17 +/- 1 versus 25 +/- 2 (p = 0.0001), suggesting the increase was in smaller HDL particles. This was confirmed by native gradient gel electrophoresis. This was not due to aberrant metabolism of human apoA-I in the mouse, since human apoA-I was distributed throughout the HDL particle size range and was catabolized at the same rate as mouse apoA-I. In another study of 23 transgenic mice, HDL-C and human apoA-I levels were highly correlated (r = 0.87, p less than 0.001). The slope of the correlation line also indicated the additional HDL particles were in the smaller size range. We conclude that human apoA-I can be incorporated into mouse HDL, and excessive amounts increase HDL-C levels primarily by increasing smaller HDL particles, comparable to human HDL3 (HDL-C/apoA-I molar ratio = 18).
建立了五条整合了人类载脂蛋白(apo)A-I基因及不同长度侧翼序列的转基因小鼠品系。正常情况下,apoA-I主要在肝脏和肠道中表达,但所有转基因品系仅在肝脏中表达apoA-I mRNA,这强烈表明256个碱基对的5'侧翼序列足以驱动肝脏中apoA-I基因的表达,而5.5千碱基对则不足以驱动肠道表达。不同品系中人类apoA-I的平均血浆水平有所不同,约为正常小鼠水平的0.1%至200%。这与侧翼序列的长度无关。对其中一个apoA-I池大小显著增加的品系进行了脂蛋白水平的详细研究。在一项研究中,该品系的六只动物的总血浆apoA-I水平(小鼠和人类的总和)为381±43mg/dl,而匹配对照组为153±17mg/dl。与对照组相比,转基因动物的总胆固醇和高密度脂蛋白胆固醇(HDL-C)水平增加了60%(总胆固醇:125±12对78±13mg/dl,p = 0.0001;HDL-C 90±7对55±11mg/dl,p = 0.0001)。转基因动物中HDL-C/apoA-I的摩尔比显著降低,为17±1对25±2(p = 0.0001),表明增加的是较小的HDL颗粒。天然梯度凝胶电泳证实了这一点。这并非由于人类apoA-I在小鼠体内的异常代谢,因为人类apoA-I分布在整个HDL颗粒大小范围内,并且与小鼠apoA-I以相同的速率被分解代谢。在另一项对23只转基因小鼠的研究中,HDL-C和人类apoA-I水平高度相关(r = 0.87,p < 0.001)。相关线的斜率也表明额外的HDL颗粒处于较小的大小范围内。我们得出结论,人类apoA-I可以整合到小鼠HDL中,过量的人类apoA-I主要通过增加较小的HDL颗粒来提高HDL-C水平,类似于人类HDL3(HDL-C/apoA-I摩尔比 = 18)。